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From a biological view, most of the processes involved in insulin resistance, which drives 
the pathobiology of type 2 diabetes, are reversible. This theoretically makes the disease 
reversible and curable by changing dietary habits and physical activity, particularly when 
adopted early in the disease process. Yet, this is not fully implemented and exploited 
in health care due to numerous obstacles. This article reviews the state of the art in 
all areas involved in a diabetes cure-focused therapy and discusses the scientific and 
technological advancements that need to be integrated into a systems approach sus-
tainable lifestyle-based healthcare system and economy. The implementation of lifestyle 
as cure necessitates personalized and sustained lifestyle adaptations, which can only be 
established by a systems approach, including all relevant aspects (personalized diagno-
sis and diet, physical activity and stress management, self-empowerment, motivation, 
participation and health literacy, all facilitated by blended care and ehealth). Introduction 
of such a systems approach in type 2 diabetes therapy not only requires a concerted 
action of many stakeholders but also a change in healthcare economy, with new winners 
and losers. A “call for action” is put forward to actually initiate this transition. The solution 
provided for type 2 diabetes is translatable to other lifestyle-related disorders.
Keywords: type 2 diabetes, lifestyle, cure, nutrition, ehealth, reversible, system
iNTRODUCTiON
Current health care in the area of lifestyle-related diseases does not focus on reversal of the 
cause of the disease, but rather on controlling disease corollaries by manipulating biochemi-
cal pathways (gluconeogenesis by metformin, hepatic cholesterol synthesis by statins, insulin 
secretion by sulfonylureas, fatty acid housekeeping by PPAR agonists, etc.). A large repertoire 
of tools, technologies, and medicinal treatments has been developed for this purpose. Chronic 
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disease care and (cardiovascular) risk management have been 
vastly improved thanks to these possibilities. However, we are 
running into the situation that disease care soon becomes too 
costly, with a number of stakeholders that either financially 
profit from the status quo or find the effort to change it too 
complicated. Also, unbeneficial drivers in our healthcare 
economy maintain this situation, as only reductionist solu-
tions can be patented. In the context of our current healthcare 
system, citizens become patients in the literal sense of the word: 
patiently undergoing treatments instead of playing an active 
role in their own health care. In the end, this is an inefficient 
approach for treatment of the so-called “lifestyle related dis-
eases,” including metabolic syndrome, obesity, type 2 diabetes, 
and cardiovascular disease (1, 2). Moreover, we now know 
that our lifestyle partakes in the pathogenesis of many other 
diseases [e.g., inflammatory diseases like rheumatoid arthritis, 
COPD, gastroesophageal reflux disease, osteoarthritis, neu-
rological diseases like Alzheimer and multiple sclerosis, and 
specific cancers (3–5)]. Over the past 10 years, an integrated 
view on health and health care was developed, embracing 
health as a system (i.e., including systems biology concepts 
and technologies), the development of disease from health as 
a continuum and exploiting these assets toward “P4-medicine” 
(Predictive, Personalized, Preventive, and Participatory) (6, 7). 
The personalized aspect emerged from the possibilities to 
quantify the causal mechanisms involved disease predisposi-
tion (genetics) and development (environment), while the 
participatory aspect related both to the health and medical 
data ownership (8) and the need for patient citizens to take 
optimal control of all aspects of their own health, spanning all 
biopsychosocial aspects (9, 10). In this article, we will focus 
and elaborate on type 2 diabetes as an exemplary prototype 
of a lifestyle-related disease, but very similar concepts and 
approaches are valid for many other diseases. The theoretical 
framework of P4 medicine and P4 health is now solid, but 
yet difficult to translate into daily practice of health care for a 
number of reasons, mostly related to conflicting stakeholder 
interest and cost of implementation. Some examples are emerg-
ing, but mostly in an experimental and costly setting (7, 11). 
Type 2 diabetes is also interesting as the disease is not only part 
of a continuum from health to comorbidities and preventable 
but also to a large extend reversible and curable with relatively 
simple means, once P4 or P6 health is implemented, as will be 
demonstrated below.
Type 2 diabetes is a “genotype–environment interaction 
disease,” where the diabetic phenotype is expressed as a result 
of accumulated environmental pressures (wrong diet, too little 
physical exercise, disrupted sleep, and too much stress) in con-
cert with genes that render individuals susceptible to the disease. 
Over the past 50 years or so, our environment has changed in a 
way that has increased the burden of all four components men-
tioned. Reversal and cure of type 2 diabetes thus needs to focus on 
(1) biological reversal (i.e., using lifestyle as medicine), (2) 
on coping with the environmental pressures (i.e., behavioral 
change), and (3) on reduction of the environmental pressures 
(i.e., socioeconomic changes). All of these three areas will be 
discussed.
Thus, the healthcare approach toward lifestyle-related dis-
eases needs to change. Huge health and economic profits can 
be achieved if everyone would adopt an “optimal” lifestyle. This 
article presents abundant scientific evidence that major reduc-
tions in obesity, type 2 diabetes, and cardiovascular disease can 
be achieved through lifestyle interventions (12, 13). In fact, 
the (economic) benefits of a lifestyle-based therapy for type 2 
diabetes have been demonstrated in a 10-year study (14). Yet, 
the introduction of a new healthcare system for lifestyle-related 
diseases (both therapy and prevention) does not materialize 
for a number of reasons, as discussed in this article. One of 
the major motives for not using lifestyle measures in clinical 
practice is the difficulty to sustain the changes. In the short 
term, or in a rigidly imposed, lifestyle change can be achieved, 
but in long-term daily life changes easily fade away due to the 
lack of support and the many counteracting stimuli from envi-
ronmental pressure. Other major reasons for failure of lifestyle 
as medicine are the lack of economic benefits in the context of 
the current healthcare model; and the failure to use a systems 
approach instead of reductionist changes (15). Thus, theory and 
practice differ and we face a multifactorial challenge, requiring 
the removal of economic, social, psychological, and biological 
barriers.
A reorientation of health research and care is needed, start-
ing with (re)defining health and its underlying mechanisms, 
realizing that integrated participatory and personalized health 
optimization strategies are needed, redesigning the methods to 
quantify health toward the development of a new generation of 
health biomarkers (16), lifestyle interventions (17), supporting 
tools and economical values, all aiming at self-empowerment, as 
listed below.
 1. Refocusing on flexibility as core characteristic of physiology, 
allowing reversibility of disease.
 2. Diagnosis has to quantify much more than the medical 
condition. A 360° diagnosis is needed that determines all 
relevant biological, sociological, psychological, and con-
textual conditions of the patient and the trajectory toward 
disease need to be identified and quantified, to empower the 
individual to achieve a sustainable and perceivable lifestyle 
change.
 3. Interventions will need to span all relevant bio-socio-psycho-
economic factors and thus change from reductionist to sys-
temic and from generic to fine-tuning toward personal goals.
 4. Motivational tools are required in the form of personal coach-
ing as well as ICT support.
 5. Health literacy needs to be improved as part of personal health 
empowerment.
 6. Personal health data handling needs to completely refocus by 
empowering the citizen/patient valorize their health data for 
personal health and research.
 7. Together, this needs to lay the foundations of both a new 
approach in lifestyle-related health science and health 
economy.
Each of these aspects is further detailed in the paragraphs 
below.
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THe BiOLOGY
Type 2 Diabetes Can Be Cured
Although the definition of “cure,” “reversal,” or “remission” 
of type 2 diabetes has been a matter of debate (18), various 
lines of evidence have demonstrated that T2D is a reversible 
disease. Bariatric surgery generally leads to remission of type 
2 diabetes in obese people, although with large heterogeneity 
among patients (19, 20). The mechanisms are not completely 
understood, but beta-cell function recovery seems to be lim-
ited (21). Lifestyle intervention can bring about significant 
improvements in risk factors for cardiovascular disease in T2D 
patients, as indicated by a meta-analysis of studies (22). Most 
of these studies evaluated relatively “mild” monodisciplinary 
interventions (i.e., only dietary advice, or education, physical 
activity, general advice, etc.). These are discussed in detail 
below. Intensive lifestyle intervention studies have shown very 
promising results. Reversal of type 2 diabetes by omitting sugars 
and starches from the diet may reduce or even abolish the need 
for glucose control medication. Yet, from a mechanistic point 
of view, cure would only be achieved if low-grade inflammation 
and oxidative damage are reversed, insulin sensitivity has been 
restored in all relevant organs, and insulin production by the 
beta-cell is sufficient. Organ insulin sensitivity can be restored 
by various lifestyle interventions, primarily through weight 
loss and reduction of intra-organ adipose deposits. This is 
discussed in the succeeding paragraphs. Improvement of beta-
cell function by lifestyle intervention was described by Taylor 
(23). Recent mechanistic evidence documenting diet-induced 
beta-cell regeneration adds to the story (24). Finally, various 
“atypical” forms of diabetes, mostly with a monogenetic origin, 
cannot be cured by lifestyle change alone (although lifestyle 
change has a major impact on metabolic control even in those 
patients) due to their underlying cause (25). In conclusion, 
lifestyle change can restore the pathobiology of “typical” T2D 
to normal in patients who still have sufficient insulin secretory 
capacity.
Systems Flexibility As Characteristic  
of Metabolic Health and Disease
The metabolic state of patients with type 2 diabetes is routinely 
quantified in a symptomatic manner, i.e., by the fasting plasma 
glucose concentration (the acute symptom) and HbA1c (the 
accumulated symptom). Yet, these are the consequences of 
a complex network of interactions between food intake and 
fuel metabolism, involving multiple organs and biochemical 
pathways. For optimal metabolic health, each of these processes 
needs to function optimally. We argue that effective treatment of 
type 2 diabetes requires appropriate quantification of the mul-
tiple processes leading to disease itself, its progression, and its 
cure. In this context, it is important to note that type 2 diabetes 
is not a uniform disease. There are probably many subtypes with 
their own pathophysiology, born out of specific gene–lifestyle 
interactions (26). If this is the case, there is no optimal “one size 
fits all” treatment of type 2 diabetes. Each disease variant most 
likely requires its own therapeutic approach.
Most of the metabolic processes that go awry in type 2 dia-
betes have to function in a continuously changing environment 
(diet, infections, stress, temperature, exercise, etc.) where they 
strive to maintain internal homeostasis by adapting to these 
changes, usually in an hour–day timescale. Under chronic 
external stress (month–year timescale: high calorie diets, chronic 
inflammation), two major adaptation processes occur. On the 
one hand, the molecular physiology that regulates the acute 
stress response reactions accelerates to maintain homeostasis of 
the important parameters, possibly at the cost of other param-
eters. During caloric excess, plasma glucose, triglycerides, and 
inflammatory markers are initially maintained at normal levels, 
as a result of elevated concentrations of insulin, glucagon, and 
other regulatory mechanisms (27). However, prolonged caloric 
excess invokes adaptive processes like storage of excess calories 
in the form of triglycerides, which eventually may have negative 
consequences (obesity, ectopic adipose deposits, insulin resist-
ance, inflammation, and eventually impaired insulin secretion). 
We call this phenotypic or systems flexibility (28). Disease onset 
occurs when and where one or more of these adaptive processes 
fail. Importantly, diet and lifestyle play both a negative (caloric 
excess) and positive role: many nutrients serve specifically to 
optimize these “flexibility processes” (29). Already in 2002, the 
Diabetes Prevention Program demonstrated in a large 4-year 
study that, although metformin and lifestyle both were effec-
tive in maintaining fasting plasma glucose, the plasma glucose 
response to an oral glucose tolerance test (OGTT) (a core aspect 
of phenotypic flexibility) was more efficiently restored by lifestyle 
change than medication (13).
Type 2 diabetes, from a systems flexibility mechanistic 
perspective, thus can be caused by the (partial) failure of many 
combinations of processes involved in maintaining homeosta-
sis (29). Pancreatic insulin secretion, insulin sensitivity of liver, 
muscle, and various adipose depots, intestinal permeability, 
and lipoprotein metabolism are some of the processes that 
need to maintain their flexibility. Figure 1 presents an overview 
of all major processes involved in glucose control and type 2 
diabetes. It demonstrates how many processes are connected. 
A comprehensive overview of these processes is presented in 
Ref. (30).
QUANTiFiCATiON OF SYSTeMS 
FLeXiBiLiTY: STReSS ReSPONSe 
BiOMARKeRS
Current diagnostic procedures primarily focus on symptoms 
of T2D. However, parameters such as glycemia, lipidemia, and 
blood pressure fail to capture the mechanistic underpinnings of 
the disease. It is imperative to map out the metabolic anomalies 
that drive these (plasma) markers in detail, if we wish to truly 
cure T2D (31).
Due to a wide variety of reasons (genetic, epigenetic, 
exposure, diet, stress, exercise, etc.), individuals differ in their 
“wiring” of phenotypic flexibility, will react differently to acute 
and chronic (metabolic) stressors, and develop a personal trajec-
tory of metabolic–inflammatory health and disease. Appropriate 
FiGURe 1 | Systems view on processes involved in glucose control and type 2 diabetes. The processes (nodes) are colored according to their involvement with 
organs (see legend). Blue arrows (edges) indicate a positive effect of one process on another, red arrows indicate a negative effect.
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therapeutic intervention requires identification of the individual 
“weak spots” of systems flexibility, allowing personalized advice. 
The weak spot may be impaired triglyceride storage in adipose 
tissue resulting in a fatty liver for one (32), for another it may 
be impaired excretion of VLDL particles from the liver due to a 
shortage of choline, resulting in a fatty liver (33). A third person 
may accumulate liver fat due to a shortage of carnitine, causing 
inadequate fatty acid oxidation (34), etc. Each of these processes 
needs to be mapped out to carefully design a specific (food and 
lifestyle based) therapy (35). As an example, individuals with 
a muscle insulin resistance subtype profit specifically from a 
Mediterranean diet, while those with predominant resistance of 
the liver profit from a low-fat diet (36).
To better quantify the specific underpinnings of metabolic 
derangement, i.e., subtyping of phenotypic flexibility, standard-
ized metabolic stress tests are a promising option (31, 37). 
Multi-biomarker panels are needed to reflect well-defined and - 
accepted health-related processes (Table 1) that can be used as 
diagnostics of systems flexibility by quantification in response to 
standardized stress testing. This type of method now allows to 
quantify the relative contribution of many relevant processes in 
pancreas, liver, muscle, intestine, adipose tissue, vasculature, and 
TABLe 1 | Type 2 diabetes subgroup (process) dependent diagnosis–intervention strategies.
T2D subgroups (see Figure 2, based on 
processes involved)
Diagnosis (i.e., parameters of the biopassport) Potential interventions
1. Pancreatic β-cell function (impaired insulin 
secretion)
Oral glucose tolerance test (OGTT) or challenge  
test: disposition index
Fasting-mimicking diet (FMD); β-cell protective nutrients 
(MUFA, protein, vit. K, Mg, leucine); β-cell protective drugs 
(TZDs, GLP-1 analogs, DPP4-inhibition)
2. Muscle insulin resistance (decreased  
glucose uptake)
OGTT or challenge test: muscle IR index, HbA1C,  
2-h glucose
Physical activity (resistance training); Mediterranean diet; 
low-glycemic index diet; low-carb diet; low refined sugar; 
fiber (arabinoxylan, alpha-cyclodextrin, resistant starch, 
beta-glucans)
3. Hepatic insulin resistance (decreased glucose 
uptake, but increased production and release)
OGTT or challenge test: hepatic IR index, fasting 
glucose
Low (saturated) fat diet; weight loss; very low-caloric 
diet; intermittent fasting; wholegrain; choline; carnitine; 
resveratrol; cinnamon extract; metformin
4. Adipocyte insulin resistance and lipotoxicity Basal adipocyte insulin resistance index, non-
esterified fatty acids, visceral and ectopic fat 
percentage
Intermittent fasting; FMD; α-lipoic acid; poly-unsaturated 
fatty acid/SFA balance; omega-3 FAs; TZDs; acipimox
5. Vasculature Blood pressure, LDL-cholesterol, HDL-cholesterol, 
fasting, and post-prandial triglycerides
DASH diet; low-sodium diet; wholegrain; fiber (pectin, 
β-glucan); beet root (extract); lycopene; Vit. C; Vit. K; cocoa 
flavonols; hydroxytyrosol (olive oil); monacolin K; coenzyme 
Q10; grape seed extract; chitosan/phytosterols; L. reuteri 
NCIMB 30242; statins; blood pressure lowering medication
6. Chronic low-grade inflammation CRP, total leukocytes, cytokines Physical activity; fish oil/n-3 fatty acids; Vit. D; Vit E.; Mg; 
flavonoids; curcuminoids; salicylates; TNF-α inhibitors
Currently, six processes involved in T2D are identified, and for each of them a biomarker approach to quantify the process, and an intervention strategy to optimize/restore, is 
suggested.
TABLe 2 | Examples of diagnostic parameters relevant for type 2 diabetes in 
each of the four areas covered by 360° diagnosis.
Bio Psycho Social Spiritual
Metabolic status Dietary preferences Peer pressure Eudaimonic 
well-being
Systems flexibility Stress resilience Food/sports availability Life goals
Dietary intake Personality type Family habits Worldview
Physical activity Coping styles Work environment Religion
Genetics Health literacy Mindfullness
Finances Gratefullness
database has cataloged many of these parameters for obesity and 
diabetes treatment in the behavioral, biological, environmental, 
and psychosocial areas1 and, depending on goal, type of interven-
tion, selections can be applied.
Future biomarker developments in T2D may include the 
combination of personal genome, phenotype, and environment 
(“Exposome-Phenome-Diseasome Associations”) as proposed 
by Vasan and Benjamin (43), based on the concept of network 
interactions (“diseasome”) of all relevant information, spanning 
from genetics to social interactions, already proposed 10  years 
ago (44).
THe iNTeRveNTiONS
Only Systems interventions will work
As explained above, type 2 diabetes is multifactorial and 
thus requires systems interventions. This implies that all 
1 www.gem-measures.org (accessed October 1, 2017).
5
van Ommen et al. From Diabetes Care to Diabetes Cure
Frontiers in Endocrinology | www.frontiersin.org January 2018 | Volume 8 | Article 381
kidney in type 2 diabetes, within a single metabolic challenge test 
(38) based on a multiomics assessment of these changes (39–41). 
The “amplitude” and the “duration” of disturbance (time needed 
to get back to homeostatic conditions) are taken as readout. It 
is of critical importance for proper diagnosis to develop such 
standardized (metabolic) stress tests.
Toward a “360° Diagnosis”
Apart from the above-mentioned extension of biomedical diag-
nosis to “systems flexibility subtyping,” other factors or criteria 
are important for further subtyping or personalization in lifestyle 
interventions for type 2 diabetes subjects. Examples are personal 
motivation, diet or lifestyle preferences, contextual (e.g., envi-
ronmental, social, or economic circumstances), health literacy, 
psychological stress level of a person’s daily life. Ideally, all of 
these factors are taken into account in an integrated personalized 
treatment and lifestyle change.
Such a “360° diagnosis” provides input into the shared decision 
of patient and professional on how to act and why. For example, 
it is well established that psychological comorbidities (depression 
and anxiety disorders), socioeconomic factors (education, debts, 
shift work), health literacy, and personality traits (deficits in 
problem solving or coping skills) can all hamper lifestyle change, 
self-management, and drug adherence (42) (Table 2). More so, 
it might be wise for some patients to first tackle mental disor-
ders, debts or unemployment, and then actively work on diet or 
exercise.
Furthermore, type 2 diabetes follow-up should not only 
include biological measures of systems flexibility but also an 
inventory of critical patient characteristics to set the stage for 
comprehensive, integrated care (42). The Grid Enabled Measures 
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underlying causes are quantified and addressed in a personalized 
and (chrono-)logical order. These causes fall into categories span-
ning the range of biological, psychological, sociological/environ-
mental, and spiritual domains. Interventions likely fail if one or 
more of these domains are not properly addressed, or when the 
interaction between each of these domains is not well understood. 
It also means to go beyond the treatment of symptoms, but rather 
to understand the syndemics behind health problems (45). Each 
type of intervention is addressed in detail below. Some common 
features that should mark all interventions include
 1. The efficacy of a systems approach is based on its individual 
components and a tailored analysis of the best combination of 
components (15).
 2. Interventions for lifestyle-related diseases need to be based on 
“self-empowerment.” Most externally imposed interventions 
are not sustainable. This is the case for the large majority of 
interventions, with the LookAHEAD study as prime example 
(46).
 3. Interventions always aim to improve flexibility and/or 




There is no doubt that caloric restriction and weight loss amelio-
rate metabolic anomalies in patients with T2D (47, 48). Indeed, 
loss of 5% of bodyweight or more reduces HbA1c, lipoprotein 
levels, and blood pressure. Restricting energy intake to 600 kcal/
day for 8 weeks normalizes beta-cell function and hepatic insulin 
sensitivity in obese type 2 diabetics, coinciding with reduction of 
hepatic and pancreatic fat content (23, 49, 50). These data clearly 
indicate that type 2 diabetes is a reversible disease, which can 
be cured by appropriate dietary measures (although the genetic 
predisposition obviously never disappears). Interestingly, upon 
publication of the data, many T2D patients reported similar 
effects of very low calorie intake in their daily life practice, dem-
onstrating that the disease can also be reversed in a non-research 
self-empowerment setting (51). (Severe) caloric restriction is 
difficult to sustain, if not plain deleterious in the long run. Thus, 
the “DiRECT” study was designed as a 4-year demonstrator of 
the above-mentioned caloric restriction, where the treatment 
of 149 type 2 diabetes patients consisted of withdrawal of 
antidiabetic and antihypertensive drugs, total diet replacement 
(~850 kcal/day formula diet for 3–5 months), stepped food rein-
troduction (2–8 weeks), and structured support for long-term 
weight loss maintenance. The first-year results are published 
and show remission of type 2 diabetes (i.e., HbA1c below 6.5% 
without medication) in 48% of the subjects, while the control 
group (standard care) showed 4% remission. Interestingly, the 
remission was associated with weight los, with subjects losing 
more than 15 kg showing 86% remission (52).
(Intermittent) Fasting
Fasting, including caloric energy restriction and different inter-
mittent fasting regimes, has been shown effective in weight loss, 
improving insulin sensitivity, and decreasing cardiovascular risk 
in both non-diabetic and diabetic subjects (53–56). A study by 
Halberg et  al. in which participants followed an alternate day 
fasting scheme while maintaining body weight and fat mass, still 
demonstrated increased insulin-mediated whole body glucose 
uptake rates, insulin-induced inhibition of adipose tissue lipoly-
sis, and increased plasma adiponectin levels (57). This suggest 
that the positive effects of intermittent fasting are not solely 
attributable to weight loss, but are also driven by other mecha-
nisms enhancing metabolic/phenotypic flexibility. The profound 
metabolic benefits of intermittent and periodic fasting have been 
well documented in preclinical experiments. For example, alter-
nate day fasting (i.e., complete fasting for 24  h alternated with 
24 h periods of ad libitum intake) fully reverses the high insulin 
and glucose levels of db/db diabetic mice to normal, despite 
similar overall food intake and stable bodyweight compared to 
ad libitum fed animals (58). However, fasting every other day is 
probably even less realistic than chronic calorie restriction and its 
effects in humans are poorly understood (59). The periodic and 
prolonged use of the so-called fasting-mimicking diets (FMDs) 
may offer an effective and safe alternative for the treatment of 
T2D in humans. FMDs are meal replacement plans, mimicking 
the endocrine and metabolic effects of fasting while containing 
modest numbers of calories. The characteristics of these diets that 
are critical for appropriate copying of the effects of total fasting 
(despite considerable calorie content) are lack of refined carbo-
hydrate, a very low-protein content and high levels of healthy 
fats, all from plant-based sources (60). Both animal and human 
studies suggest that FMDs can be applied as infrequently as once 
a month for 5 days, requiring approximately 50% reduction in 
calories to be effective in promoting strong effects on metabolic 
syndrome risk factors (61, 62). Remarkably, and in keeping with 
previous reports (58), animal studies indicate that the effects of 
the periodic FMD on disease risk factors does not require overall 
calorie restriction, since mice on the FMD consumed the same 
number of calories per month as mice on the ad libitum diet (61). 
The molecular mechanisms that underpin the benefits involve 
the persistent endocrine and metabolic shifts typically induced 
by fasting: (1) reduction of (bioavailable) insulin growth factor-1, 
insulin, ectopic fat storage, and endogenous glucose production; 
(2) increased adipose lipolysis and fat oxidation; and (3) use of 
glycerol and ketone bodies instead of glucose as preferred carbon 
sources (59). Notably, recent experimental evidence suggests that 
periodic use of FMDs can drive beta-cell regeneration to restore 
insulin production in animal models of type 2 (and type 1) 
diabetes (24). The potential benefits of intermittent fasting could 
lie in “flexibility training”; i.e., the frequent switching between 
metabolic modes, from glucose to free fatty acids and ketone 
bodies as energy source, i.e., inherent to fasting (59). This find-
ing is in line with the positive impact of intermittent fasting on 
insulin sensitivity, inflammatory markers, oxidative damage, and 
stimulation of autophagy (59, 63, 64).
Some studies, however, did show adverse effects of intermit-
tent fasting in healthy, non-obese subjects, including increased 
levels of free fatty acids and impaired glucose tolerance (65, 66), 
suggesting that intermittent fasting should only be applied in 
metabolically inflexible persons.
No studies as yet have been performed that compare effec-
tiveness of an isocaloric intermittent fasting scheme and caloric 
energy restriction, or healthy diet intervention. Such studies are 
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required to confirm the ability to “train” metabolic flexibility with 
intermittent fasting.
Collectively, currently available evidence strongly supports 
the clinical potential of periodic fasting as an effective and safe 
alternative to chronic restriction of calories. FMDs may be a 
feasible mode to implement this therapeutic strategy.
Macronutrient Composition
The macronutrient composition of food is relevant for metabolic 
control as well. As mentioned above, in theory, abolishing the 
need to store excess glucose by low-carbohydrate (particularly 
sugar and starch restricted) diets obviates the need for glucose 
lowering medication, simply because there is no glucose to be 
stored. Numerous studies have been performed with low or 
poorly digestible carbohydrate in type 2 diabetics [e.g., Ref. 
(67–71)]. Follow-up was 1 year in most of them. The data sug-
gest that, in the short term (4 weeks to 6 months), carbohydrate 
restriction is effective in terms of glucose and weight control. 
However, in the long run, the effects in terms of bodyweight, glu-
cose control, and lipid profiles of low-carbohydrate diets do not 
appear to be superior to those of high-carbohydrate diets (72). 
A meta-analysis of intervention studies (in diabetic and non-
diabetic humans) revealed that substitution of carbohydrates 
with poly-unsaturated fatty acids significantly reduces plasma 
HbA1c and insulin, while replacing carbohydrate with saturated 
fat reduces only insulin levels somewhat (73). Besides carbs and 
fats, effects of dietary protein on diabetes type 2 also received a 
lot of attention in literature. The acute insulinotropic effects of 
especially whey protein have been quite well established (74). 
This effect seems to be mainly driven by an increase in GLP-1, as 
well as decreased gastric emptying (75, 76). However, increased 
insulin production is not a beneficial effect if not accompanied 
by increased insulin sensitivity. Overstimulation of the pancreas 
and stimulation of gluconeogenesis by high-protein diets may 
in the long term even result in increased (muscle) insulin resist-
ance (77), if not compensated by increases in lean muscle mass 
or weight loss (78, 79). It can thus be concluded that manipulat-
ing the macronutrient content of the diet without restriction 
of calories does not cure T2D in the vast majority of patients, 
although it can improve the diabetic phenotype to a certain 
extent.
Micronutrients and Non-Nutrients
Many micronutrients and non-nutrients were shown to improve 
glucose control, interacting with a large variety of pathways 
and processes. Interestingly, almost all processes involved in 
maintaining systems flexibility (see above) are targets of micro- 
or non-nutrients. These are summarized in many dedicated 
reviews (17, 29, 80, 81). Micronutrients are involved in ectopic 
lipid disposition [e.g., choline deficiency reduces fatty acid oxi-
dation (82, 83) and hampers VLDL particle synthesis, and thus 
stimulates fatty liver (84)]. Various nutritional therapies were 
shown to be efficacious for non-alcoholic fatty liver disease (84). 
Nutritional anti-inflammatory compounds (e.g., polyphenols, 
omega-3 fatty acids) contribute to reversing type 2 diabetes, 
although primarily in combination with other interventions 
(85), and in a gender-specific manner (86). Insulin secretion 
is optimized by zinc (87), magnesium (88), and vitamin D 
(coinciding with its effect on inflammation and glucose control) 
(89). In theory, a healthy diet should suffice in the needs of these 
micronutrients. Given the fact that type 2 diabetics usually do 
not have a track record in healthy eating, targeted prescription 
of micronutrients and non-nutrients may be required. Diagnosis 
of the malfunctioning components of systems flexibility in T2D 
(or any other disease) will allow the design of specific (nutri-
tional) therapies.
Personalization
One of the reasons for the lack of consistent, significant effects 
of the dietary interventions described above probably pertains 
to the fact that people are not born or raised equal. Moreover, as 
described in the previous paragraphs, systems diseases require 
systems diagnosis based on quantifying phenotypic flexibility. 
This reveals the underlying physiological disease cause(s), 
embedded in a complex network of metabolic and inflammatory 
processes. For optimal systems flexibility, each process needs to 
function optimally. In type 2 diabetes, many organs and processes 
can contribute to disruption of (glucose) metabolism (90). The 
degree of insulin sensitivity of the three main organs involved 
in maintaining glucose homeostasis (muscle, liver, and adipose 
tissues), and the degree of insulin excretion by the pancreas can 
be assessed by measuring glucose and insulin at 30-min intervals 
during an OGTT, together with fasting free fatty acids (16). 
The severity of insulin resistance can differ between the various 
organs, and different interventions may have organ-specific 
effects related to increasing insulin sensitivity (91), as demon-
strated by the example of treatment of type 2 diabetic patients 
with a very low-caloric diet (VLCD) or physical exercise. When 
insulin resistance primarily affects muscle, physical exercise 
rapidly restores glucose tolerance (92). In contrast, patients with 
insulin resistance of the liver respond particularly well to VLCD 
(23). However, when β-cell capacity is not sufficient, neither 
VLCD nor physical exercise will fully reverse glucose tolerance 
(23, 93–95). Similar tissue-specific metabolic effects of distinct 
interventions were also demonstrated in the CordioPrev cohort, 
where the Mediterranean diet specifically improved glucose 
metabolism in T2D patients who predominantly had muscle 
insulin resistance, while a low-fat diet specifically benefited 
patients with liver insulin resistance (36). These observations 
are supported by mechanistic data on metabolic flexibility, 
demonstrating differential molecular routes for insulin resist-
ance in distinct organs (96). This begs for systems interventions 
based on diagnosis of decreased flexibility of (tissue-)specific 
health-related processes. In taking this concept further, toward 
all aspects of phenotypic flexibility, Table 1 gives an example of 
how we envision systems diagnosis and related interventions for 
T2D. Many systems biology based examples of nutrient–flex-
ibility–health relationships and the ways in which they can be 
personalized have been reviewed (29). In the area of hyperten-
sion, an “integrative approach” was proposed, using a multitude 
of food products and supplements on top of the DASH diet (97). 
Recently, an international panel recommendations for the pre-
vention and management of metabolic syndrome with lifestyle 
also showed clear scientific evidence for lifestyle treatments based 
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on weight loss and increased energy expenditure through physi-
cal activity, for a Mediterranean-type diet, with or without energy 
restriction, as well as for other similar dietary patterns, next to 
quitting smoking, reducing intake of sugar-sweetened beverages 
and meat products (17).
Physical Activity interventions
There is strong evidence for the beneficial effects of physical 
activity on insulin resistance, type 2 diabetes, dyslipidemia, 
hypertension, and obesity (98, 99). Even a single exercise bout 
improves blood pressure, glycemia, carbohydrate oxidation 
during exercise, and fat oxidation after exercise (100). Physical 
activity programs were shown to be effective in NAFLD treat-
ment (101). Specific physical activity programs achieve specific 
metabolic health improvements. For example, high-intensity 
intermittent exercise was shown to specifically reduce liver fat 
(102). Sixty minutes of walking resulted in a 75% increase of 
whole body insulin sensitivity (103). On the other hand, just like 
overeating, lack of physical exercise as such is associated with a 
number of lifestyle-related diseases (104–106). Physical activity 
programs can be targeted to specifically reduce ectopic fat and 
thus become part of a lifestyle program for T2D. A meta-analysis 
indicated that especially endurance training (aerobic exercise) 
had an effect on visceral fat and possibly intrahepatic fat in type 
2 diabetics (107).
Mechanisms involved are restoration of metabolic flexibility, 
the oxidative part of insulin resistance, and reducing the reactive 
oxygen species production. Also, physical activity attenuates 
inflammation in a positive manner, which contributes to man-
agement and reversal of type 2 diabetes (108). Most of these 
mechanisms involve the mitochondria and are especially valid for 
the muscle (109), suggesting a specific benefit of physical activity 
for patients with muscle insulin resistance.
The Role of Medication in Lifestyle 
Therapy
The current pharmaceutical approach to diabetes care is to 
assist the patient in maintaining glucose, lipid, and blood pres-
sure control. Metformin primarily decreases hepatic glucose 
production. Thiazolidinediones assist in fatty acid storage in 
adipose tissue, thereby increasing the use of glucose as energy 
source and reducing ectopic fat storage. Sulfonylureas stimu-
late insulin secretion, DPP4 inhibitors prolong the half-life of 
insulin-stimulating hormones, and exogenous insulin facilitates 
organ glucose uptake. Medication is prescribed depending on 
the stage and severity of the disease. Yet, none of these medica-
tions addresses the root cause of T2D and will thus not cure the 
patient.
Plant-based diets almost immediately reduce the need for 
insulin in “insulin-dependent” type 2 diabetics (110), because 
absorption of complex carbohydrates from plants just modestly 
increases plasma glucose levels, which obviates the need for insu-
lin to facilitate glucose storage. Very strict low calorie (600 kcal/
day) dieting restores plasma glucose concentrations to normal in 
T2D patient in 1 week (23). Yet, although such intervention initi-
ate the reversal of type 2 diabetes, the trajectory toward real cure 
(i.e., restoration of organ insulin sensitivity and beta-cell insulin 
excretion) will take much more effort and time. Meanwhile, 
medication may be needed. Therefore, a lifestyle intervention as 
therapy for T2D will need to be supervised by medical profes-
sionals. Notably, patients who choose to adopt lifestyle changes to 
treat their T2D often need to convince their doctors to adapt their 
medication. Doctors generally consider medication as required 
for glucose management (111).
In a fully integrated approach to cure of T2D, lifestyle and 
medication should (sometimes) be combined. Pharmaceutical 
strategies should be designed to support optimal reversal of 
tissue insulin resistance and beta-cell failure, i.e., a combined 
“precision medicine/precision lifestyle strategy.” As described 
above, type 2 diabetes essentially needs a systems view, systems 
diagnosis, and systems therapy to restore insulin sensitivity of all 
relevant tissues (liver, muscle, and adipose), and reactivation of 
beta-cell insulin secretory capacity. The extent to which insulin 
sensitivity and/or action are compromised in each of these 
tissues may differ between patients. Therefore, the treatment 
strategy should be tailored to personal disease characteristics. 
For example, hepatic insulin resistance due to hepatosteatosis in 
a relatively lean subject may be due to impaired fatty acid uptake 
by subcutaneous fat or by excessive consumption of refined 
carbohydrates. Combining a PPAR agonists with restriction of 
sugar (and alcohol) intake could be a beneficial “food-pharma” 
couple.
Depending on the disease progression, two other aspects 
related to medication need to be taken into account. First, not 
all aspects of systems flexibility may be fully restored, as irrevers-
ible damage may have occurred. For example, impaired insulin 
production can be reversed by reducing pancreatic fat storage 
and glucose toxicity (112), but beta-cell damage may not be fully 
reversible. Second, not all comorbidities and pathologies resulting 
from hyperglycemia are reversible, although the causal drivers 
(obesity, hypercholesterolemia, hyperglycemia) can be reversed. 
Indeed, cardiovascular, renal, ocular, and neural complications 
might need specific medication.
Sustained Behavior Change
A lasting change in health requires sustainable lifestyle changes 
of individuals and active self-management. Behavioral change 
interventions are designed to affect the actions that individu-
als take with regard to their health. These interventions can be 
directed at the individual via psychological determinants of 
behavior, or target their social or physical environment to create 
a supportive environment.
First of all, for sustained behavior change, various phases 
need to be confronted. Initiation of behavior change is by no 
means a guarantee for continuation. Rothman et al. suggested 
four phases of behavior change: behavioral initiation, continu-
ation, maintenance, and habit (Table 3) (113). Before the phase 
of initiation of new behaviors, old habits (like unhealthy eating) 
are prominent. In the phases of initiation and continuation, the 
newly adopted behaviors can be in conflict with old patterns, 
and within this phase the relapse to old habits is likely. If the 
new behavior becomes the dominant response across context, 
and people are able to override previous automatic responses, 
maintenance, and habit become likely. Each phase needs tailored 
TABLe 3 | The various phases in behavioral change, together with the 




Onboarding Identification—who am I Motivational interviewing 
and tailoring
Initial effort I want this
I can do this
I believe the new behavior will 
help me to realize my goals





Continue effort I know my obstacles and I  
can overcome them
I can maintain the new behavior
Problem identification  
and solving
Coping planning and self-
monitoring, self-evaluation
Sustained effort I enjoy the new behavior and  
its results




Prompt repetition in  
various contexts
Habit It is part of who I am ☺
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behavior change strategies (113). Whereas the initiation phase 
is mainly based on outcome expectations and efficacy beliefs, 
continuation depends on the reward gained from the behavior 
and self-regulatory skills like planning, sustained self-efficacy, 
self-regulatory effort, including self-monitoring (114, 115). 
Maintenance has been linked to factors like self-identity, sat-
isfaction/enjoyment of the new behavior (116). A new habit 
is achieved when the newly formed behavior has become the 
automated response.
Behavior change interventions have been effective in creat-
ing changes in physical activity and dietary intake (117, 118) 
and have resulted in changes in HbA1c levels (119), especially 
for those with a higher baseline HbA1c and for interventions of 
at least 1 year. Behavioral maintenance of physical activity and 
dietary behaviors can be achieved when these interventions are 
conducted over a longer period (>24 weeks), include face-to-face 
contact, multiple intervention strategies, and follow-up prompts 
(120). The effectiveness of these interventions depends on the 
balanced combination of behavior change strategies to promote 
and support behavior change (118).
Studies that have effectively supported type 2 diabetes patients 
have been based on:
 – prompt focus on past success (identifying and emphasizing 
successful behavior change from the individual’s past);
 – barrier identification/problem-solving (identifying salient 
barriers to physical activity for the individual and strategies 
to overcome them);
 – use of follow-up prompts (such as reminder postcards or 
motivational telephone calls);
 – provide information on where and when to perform the 
behavior (individuals are given explicit information on loca-
tions, times, and opportunities available locally for changing 
physical activity behavior);
 – prompt review of behavioral goals followed by revisions or 
adjustments (121);
 – maintenance motives (focusing on reward of changing the 
behavior) (122);
 – environmental restructuring (to facilitate the desired behav-
ior) (123).
Lifestyle change is not an effortless or innately pleasurable 
process for most people. Thus, engaging in healthy behaviors 
needs to be fulfilling or rewarding—until the long-term benefits 
of the new healthy lifestyle become manifest and the new lifestyle 
has become habitual. Reward-based reinforcement is a much-
researched learning theory strategy to promote behavior change, 
which includes vicarious reinforcement (imitating behaviors of 
others who have experienced rewards due to the behavior) and 
incentives [which can be (financial) presents]. Incentive-based 
interventions have been successfully applied to various areas of 
behavior change, ranging from smoking cessation and physical 
exercise to counseling attendance and medication adherence 
(124). Reward-based approaches address the principle that 
people are prone to succumb to instant gratification, rather than 
investing for the future. Some people are more prone to instant 
gratification, and it is often associated with the immediate 
reward of eating. Meta-analytical evidence shows that providing 
(financial) incentives is an effective strategy in health behavior 
change (124). As a consequence, reward-based programs have 
gained a lot of interest among policymakers and governments. 
Both the United States and the United Kingdom governments 
advocate the use of incentives to encourage healthy lifestyle 
choices and have started large-scale reward programs that 
target vulnerable populations. In South Africa, health insurer 
discovery has developed an advanced reward program that col-
laborates with businesses to form a “lifestyle loyalty” program. 
Participants earn reward points for all kinds of health activities 
and behaviors, and the points can be exchanged for goods and 
discounts at local and national businesses. Active participation 
in the program showed to increase exercise, healthy food pur-
chases, and decrease healthcare costs. A comparable approach 
is adopted in the Netherlands for cardiac patients and could be 
easily adjusted to type 2 diabetes.
Persuasiveness is a key element to promote behavioral 
maintenance and adherence to interventions (125). Although 
monetary rewards may function as incentives, other types of 
persuasive design methods of [ehealth (eHealth)] interventions 
have been examined as a means to increase engagement with 
interventions and behavior change. Whereas the behavior-
change strategies are mainly targeting primary task support, 
supporting behavior change, other persuasive design features 
focus on dialog support, increasing attractiveness of interven-
tions or the reward of behavior change. A particular persuasive 
strategy is gaming or gamification principles. These so-called 
serious games are not only meant to entertain but also aim to 
educate or promote behavior change. Serious games can promote 
the use and adherence to behavior change interventions. Indeed, 
a recent meta-analyses examining the role of video games in the 
promotion of lifestyle changes, suggested that serous gaming is 
effective, albeit to a limited extend (126, 127). A particular type 
of gaming has been exergaming or active video games, which are 
games that require physical activity. These include games, such 
FiGURe 2 | Schematic representation of a personal cure and maintenance trajectory. Depending on the personal 360° diagnosis, the duration and intensity of the 
cure and maintenance phases and the relative contribution of the components may vary.
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as dancing games, which generally are done indoor. Exergames 
seem to be able to contribute to physical activity and bodyweight 
control, although the effects appear to be limited in uncon-
trolled settings, and keeping people involved seems a challenge 
(128, 129). Nevertheless, with the emergence of new types of 
mobile exergames, for instance, using combined virtual reality 
and stimulating physical activity at any time and place, exergam-
ing may have potential (130).
Therapeutic alliance is another type of engagement strategy. 
Therapeutic alliance has been defined as a non-specific feature 
of treatment, reflecting the extent of collaboration, purposeful 
action, and emotional connection between a client and therapist. 
Within the context of interventions guided by healthcare workers, 
it has been shown that therapeutic alliance increases adherence 
and effectiveness (131). Also in eHealth interventions, therapeu-
tic alliance has been shown to enhance engagement (132, 133). 
This certainly is important, as early dropout tends to occur during 
eHealth interventions.
Lifestyle-based therapy aims to results at reversing and pos-
sibly curing type 2 diabetes. Reversal may be achieved within a 
relatively short period (weeks to months, depending on intensity 
of the program and severity of the diabetic state). After this “cure 
phase,” continued support may be helpful lifelong, both focusing 
on maintaining an optimal lifestyle and on supporting behavior. 
Figure 2 presents a schematic overview on the various phases, 
mentioning some of the important components that can be 
applied during the various phases.
Health Literacy
Health literacy in type 2 diabetes is often but not unambiguously 
associated with glycemic control and other disease endpoints 
(134). Since care and cure of type 2 diabetes heavily depend on 
self-management, and since this is a complex matter involving 
many aspects of information, awareness, reasoning, and knowl-
edge, health literacy is of high importance. As mentioned above, 
health literacy should be taken into account when diagnosing a 
patient.
Health literacy methods are the topic of research and 
evaluations on their efficacy are in progress. Taken together, 
multiple aspects and approaches are available and real-life 
implementation in a tailored, if not personalized manner involv-
ing all stakeholders needs to be part of the diabetes care and 
cure agenda (135).
Structural interventions for Risk Groups
Besides individual support, structural interventions should be 
initiated for particular groups of people with T2D that hamper 
changing their lifestyle due to social–contextual constraints, 
including neighborhood characteristics, availability of foods, 
poverty, the local role of primary care, etc. (136). Structural 
interventions, i.e., interventions aimed to alter the context in 
which people are living, are likely to promote sustainability and 
may have additional positive effects on people, besides lifestyle 
changes and changes in physical health, such as lower experi-
enced loneliness, improved social cohesion, etc. (137). This in 
particular may be needed for people at risk, e.g., citizens of low 
socioeconomic gradient, as they are often experiencing a multi-
tude of problems, which need to be targeted by interventions to 
enable them to effectively change their lifestyles (138). Solutions 
are sought in community-oriented multidisciplinary primary 
care interventions in many countries.
eHealth and mHealth in Type 2 Diabetes
Information and communication technologies, i.e., eHealth, can 
facilitate health care (139). Particularly in the area of eHealth 
self-management for chronic somatic conditions, guided and 
embedded interventions have been shown to be as effective as 
face-to-face treatment but are usually more cost-effective (140). 
In type 2 diabetes, innovations in eHealth have a demonstrated 
potential for supporting patients with self-management behav-
iors, in particular dietary and physical activity behaviors, and 
may result in better diabetes outcomes such as HbA1c (141). 
Innovations that can have positive impacts on self-management 
behaviors include text messages, smartphone apps, and web-
based programs (141). Several systematic reviews showed that 
telemonitoring can improve HbA1c levels (142–144). Video 
games, virtual and augmented reality, and wearables are also 
promising, but individuals should be adequately trained in 
the use of these technologies (141). Moreover, guided eHealth 
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interventions are usually more effective than non-guided inter-
ventions (140), which urges for “blended care” solutions, so that 
eHealth is part of a structured care plan.
Thousands of mobile (mHealth) apps for diabetes are available 
for download in App stores (145). Only a small number of the 
available apps are evidence based (146). Some systematic reviews 
and meta-analyses showed that mobile phone interventions 
lead to improvements in glycemic control and self-management 
(147, 148). Apps for diabetes self-management typically share a 
limited number of basic functions, which can be classified into 
several categories, e.g., self-monitoring, education, support, 
alerts and reminders, and communication (149). To evaluate the 
effectiveness of the different functions on glycemic efficacy, Wu 
et al. developed a taxonomy of apps for diabetes self-management 
(150). In line with earlier studies, they showed that the use of 
mobile app-based interventions yields a clinically significant 
HbA1c reduction among adults with type 2 diabetes. Having 
a complication prevention module and/or a structured display 
was associated with a greater HbA1c reduction. Other functions 
(medication management, generation education, personalized 
feedback, communication, potential-risk intervention with clini-
cal decision-making) were not associated with greater HbA1c 
reductions.
eHealth and mHealth can be applied both in the manage-
ment and prevention of diabetes and thus should be embedded 
in the continuum of prevention, care, and cure. The American 
Diabetes Association stated that eHealth technologies, such as 
Internet-based social networks, distance learning, DVD-based 
content, and mobile applications may be a useful element of 
effective lifestyle modification to prevent diabetes (151). The 
US Center for Disease Control and prevention and the Diabetes 
Prevention Recognition Program have begun to certify eHealth- 
and mHealth-based modalities as effective media for diabetes 
prevention interventions that may be considered together with 
more traditional face-to-face and coach-drive programs (blended 
care). Apps for weight loss and diabetes prevention have been 
validated for their ability to reduce HbA1c in the setting of 
prediabetes (152). Traditionally, most weight loss apps focus on 
reducing caloric intake, but for people with (pre)diabetes it is 
more important to make food choices that induce normal post-
meal glycemic responses (153).
mHealth can be greatly improved when ICT technologies are 
combined with evidence-based behavior change interventions. 
It has been shown that eHealth interventions that use more 
behavior change strategies were more likely to effectively change 
health behavior (physical activity, healthy eating, weight loss) 
(118, 154). And through, e.g., cultural tailoring (e.g., tailoring 
to gender, age, religion, ethnic background, or health literacy) 
acceptance, loyalty, and effectiveness of digital health can be 
improved (155). Furthermore, computer-tailored interventions 
have become increasingly common for facilitating improvement 
in health behaviors. Dynamic tailoring (where the intervention 
variables are assessed before giving feedback) was shown to be 
more efficacious than static tailoring (all feedback is based on 
one baseline assessment) and has long-term effects (156). For all 
eHealth interventions, guided treatments are usually more effec-
tive than non-guided treatments (140).
Combining face-to-face counseling with extended care (via 
dynamically tailored support) has a potential to increase the 
effectiveness of T2D management (157). There is a clear need for 
delivery systems to use team-based models and engage patients 
in shared decision-making (SDM), where patients and provid-
ers together make healthcare decisions that are tailored to the 
specific characteristics and values of the patient. It has been dem-
onstrated that such an approach leads to patients reporting better 
understanding of diabetes and showing improved hemoglobin 
HbA1c values, while healthcare providers reported the SDM aids 
increased cohesion among team members (including patients) 
and facilitated patient education and behavioral goal setting 
(158). In a large pragmatic trial making use of motivational 
interviewing, SDM, and collaborative goal setting in chronic 
conditions, a striking difference in mortality rates was found 
after 2  years of telephone-based health coaching (OR  =  0.64; 
p = 0.005), which was achieved with an average of 12.9 calls per 
patient (159).
The value of a Timeline of the Health  
and Behavior Trajectory
Ideally, biomarkers and diagnostics develop into two dimen-
sions. First, from a single process to the complete quantification 
of health, including flexibility (“systems flexibility biomarker,” 
described above), and second, along the timeline of an indi-
vidual’s health trajectory, building the life story of systems 
flexibility, a personal “biopassport.” Loss of systems flexibility 
is a process that develops over the timespan of many years. 
Interventions are most successful in early stages, when full 
reversal and cure is possible. The storage and availability of bio-
marker data has been common practice in longitudinal cohorts, 
but the translations of its results into health care is a tediously 
slow process. Also, personal health(care) data are usually not 
available in a structured and understandable manner for the 
citizen/patient to valorize for his personal health. Since lifestyle-
related health is primarily dependent on self-management and 
self-empowerment, it is vital that the citizen/patient has access 
to all relevant health data and information (8). If biomarkers 
of phenotypic flexibility are the key in optimizing metabolic 
health and in prevention and treatment of metabolic diseases, 
they need to be measured in regular intervals. At this moment, 
this is not practical and not affordable, and moreover most 
healthcare systems neither focus on nor reimburse preventive 
diagnostics. Therefore, new diagnostic applications need to be 
developed which are cost-effective, minimally invasive in pref-
erably “do-it-yourself ” applications. Developments, both in ICT 
(personal health portals) and in diagnostics (“gadgets,” dried 
blood spot diagnostics, etc.) are rapidly disclosing this area. 
Various sensors (e.g., wearable, on-phone, at home) and other 
measurement devices (e.g., glucose monitors, weighing scale) 
have become cheaper and more user friendly. The challenge is 
to use these techniques in a complementary manner (160). As 
an example, the “Nutrition Researcher Cohort” (161) started 
this movement in 2011. However, this cohort encountered 
major obstacles related to research ethics as it appeared to be 
virtually impossible to merge personal health data collection 
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with “citizen-science” research, and a further development of 
“participant led research is needed” (162). The NIH “All of Us” 
cohort as part of the Precision Medicine Initiative is profes-
sionalizing this movement (163), although not focusing on 
lifestyle. New, partly commercial activities are maturing this 
area (11). Also, “big data” and artificial intelligence-derived 
solutions are emerging for clinical decision support, like IBM’s 
health analytics (164). Finally, apart from the above-mentioned 
developments that shift diagnosis away from the traditional 
medical domain toward self-empowerment, other more unex-
pected developments arise. Internet search engine data analysis 
is rapidly becoming a powerful tool for surveillance (165). These 
opportunities now move from surveillance to research tools 
(166), but it may take some time before they become applicable 
for personal diagnosis due to privacy and ethical constraints. 
A biopassport is the ideal starting point for the design of lifestyle-
based personal health optimization and self-empowerment 
strategies. The biopassport can be extended with the above 
described “360° diagnosis.” eHealth applications can be tapped 
into the biopassport to deliver advice and guidance. Ecologi-
cal Momentary Assessment/Intervention application can be 
embedded in and will enrich the biopassport (167). Essentially, 
the personal availability of the timeline of health data will trig-
ger a wealth of applications and economic developments that 
support personal healthy living and lifestyle-based therapies.
Health Data Cooperatives As Ultimate 
Platform of Health Democracy
Science, business, and society now begin to realize the value 
of citizen-owned health data (8). Numerous participant or 
patient centric initiatives have emerged, either from within or 
outside the healthcare institutions, both commercial and non-
profit, and all of them based on Internet and social networking 
(168, 169). An enormous power is being unlocked in extend-
ing and integrating these data, and this is acknowledged by 
investments in this area through companies like 23andMe and 
PatientsLikeMe, and activities of most major “big data compa-
nies” (170). Of course, the best entity to valorize citizen-owned 
health data for any purpose (science, health care, or economy) 
should be the legal owner, i.e., the citizen itself. The “Health 
data Cooperative” (171) may be an attractive model for this 
purpose, as it is the most democratic shared ownership and 
decision-making legal entity available. This would unlock the 
value of personal health data for the benefit of personal and 
public health, facilitate an optimal merge between healthcare 
quality management and research, and provide the citizen/
consumer/patient with the power to become the center of 
health care. If indeed the economic value of health data can be 
invested for the genuine benefit of the citizen/consumer/patient 
instead of commercial stakeholders, this has the potential to 
disrupt the current healthcare system into a citizen-centered 
and self-empowering healthcare system and economy, where 
services can be implemented that can optimize health, prevent 
lifestyle-related disease, and cure these using the right tools. 
Among the right tools should be support of a structured 
population health management strategy aiming at stratification 
of the population with T2D according to their risk of various 
relevant adverse health outcomes. This can be realized with 
linkage and advanced analysis of (when needed coded and 
anonymized) routine healthcare data from all domains, result-
ing in a structured approach of individuals who are member of 
subpopulations sharing defined risks.
Toward integrated “Companion Systems”
Once the above expose materializes in actionable interventions, 
the type 2 diabetes patients will be overwhelmed by a wide range 
of advice and information. Generally speaking, these patients have 
not shown excellence in adherence to advice nor have they all the 
skills required to adequately deal with a wide range of advice and 
information. Thus, many components line up for a new failure 
in implementation and dropout of patients after initial start. 
Especially, if we look at mHealth we see the number of mobile 
phone apps for type 2 diabetes is enormous, being the largest 
application area in the 100,000+ health Apps available in 2014 
(145). It is unlikely that any of these apps covers all areas needed, 
and it is unlikely that any significant percentage of type 2 diabetics 
will be able to sensibly maneuver among this overwhelming offer.
We therefore propose a different approach, where a multitude 
of overlapping personal advice systems applications are replaced 
by an integrated ecosystem of health services, provided to the 
end-user in an “on demand” manner based on real-time needs. 
Health services can span advice on diet, medication compliance, 
physical activity, behavioral guidance, health and product infor-
mation, community building, etc. These services should only 
be presented to the (ex-) type 2 diabetes patient when relevant 
and needed, in a format and language that is fine-tuned to the 
user’s socioeconomic–cultural needs, and optimally facilitate 
liaison with healthcare professionals. Obviously, these services 
can become very complex and may include artificial intelligence, 
ecological momentary assessment and interventions, just in time 
adaptive interventions and similar approaches. Also, a wealth of 
personal health data can be used as input, spanning from personal 
health monitoring to medical records. Yet, none of this complex-
ity should be visible to the end-user, but the interaction with this 
“life companion” should be minimized to non-intrusive essentials 
matching the health literacy of the user. Various presentation 
modes (mobile, desktop, life coaching, or SDM) are possible. 
Figure 3 presents a schematic overview of the functionalities of a 
life companion approach. Examples are emerging which combine 
the layers described above, integrating all aspects of P4-medicine 
(personalized, predictive, preventive, and participatory) with 
data- and knowledge drive advice systems in the area of type 2 
diabetes (172).
THe eNviRONMeNTAL SUPPORT
Most of the arguments presented above deal with optimizing the 
biological interventions within a self-empowerment behavioral 
change setting. Yet, if we agree that a systems solution is the only 
way forward toward a cure, the other side of the equation also 
needs to be addressed, i.e., coping with the diabetogenic envi-
ronment, and ideally changing the diabetogenic environment 
(Table 4). Behavioral change technologies connected to eHealth 
TABLe 4 | Type 2 diabetes is a systems disease where solutions need to be 
found in all three systems mentioned to achieve a transition from care to cure.
Social system Physiological system Healthcare system
T2 diabetes is a “systems disease”
Obesogenic environment
Limited engagement with 
health status




T2 diabetes initiates when 




No focus on prevention
Short-term financial 
vision




Integration of medical, 
social, economical, and 
mental solutions
Diagnosis of all 
relevant processes and 
predispositions
Goal: regain flexibility in 
all relevant processes, 
exploiting diet, lifestyle, 







FiGURe 3 | Schematic overview of a “life companion” approach. The citizen–patient interacts with a single ehealth (eHealth) platform (any combination of phone, 
desktop, life coach, healthcare provider) and receives interventions in all relevant areas (diet and lifestyle, behavior, information, etc.) at the right time in the right 
message format, based on both initial and continued diagnosis. The intervention is generated by “health services,” i.e., models that exploit personal health and 
behavior data. Timelines of diagnostic and intervention information are owned by the citizen/patient and may be shared within a community (health data 
cooperative), thus further strengthening the personal health data service with a “big data” component.
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solutions and personal health data valorization are essential in 
coping with both the biological and environmental pressure to 
consume calories. Other components of the system entail the 
environmental support. This includes family, community, and 
other social structures, primary healthcare centers, other health 
services, food providers, policies, and regulations. The efficacy 
of these “population based lifestyle interventions” has been 
reviewed (173) and evaluated (174), where, six categories of 
interventions were taken into account, ranging from educational 
campaigns to taxation. Apart from the efficacy assessment of 
each of these approaches, a clear statement was made about 
the need of a combined, “systems” approach (15). The Chicago 
based South Side Diabetes Program is a rare example of a systems 
approach taking into account all these levels in a real-life setting 
(175, 176). This program demonstrates how a multitude of tools 
(or “interventions”) can be implemented in, and fine-tuned 
toward a socio–ethnic–economic setting, involving various levels 
of society. It also demonstrates the complexity and the hurdles 
of implementing such neighborhood programs outside and 
independent of research funding. Essentially, for such programs 
to become effective and sustainable, they need to be fully incor-
porated in a profitable economic system.
The Role of the Healthcare System
The healthcare system will need some adaptations to embrace 
a lifestyle-based cure program for type 2 diabetes, as prototype 
for many others to follow (Table 4). Healthcare systems vary by 
country but some generic issues might be addressed. A better 
education on diet and lifestyle for medical professionals is needed. 
A financial system which allows for early investments in lifestyle-
based cure (diagnosis, coaching) instead of postponing spending 
until comorbidities emerge would facilitate implementation. 
Also, the need for “evidence based accreditation” connected to 
reimbursement by insurance companies might be a relaxed a bit 
as the type of lifestyle interventions discussed in this article will 
never have the economic value to justify “pharma-like” studies. 
As alternative, the “citizen-science” approach discussed above will 
slowly substitute the randomized controlled trials now promoted.
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The economy of Healthcare: From Disease 
Focused Products to Health-Oriented 
Services
A sustainable shift toward healthier lifestyle will not be easy to 
achieve. In fact, until now, neither scientific experiments nor 
implementation of lifestyle changing programs have demon-
strated their efficacy for sustained type 2 diabetes prevention 
(177). Yet, in treatment of T2D, this has been demonstrated 
(13, 14). Clearly, individuals themselves are directly responsible 
for what they eat, how they exercise, etc. However, a complex 
interplay between many external agents: regulators, industrial 
sectors, medical professionals, the media, and social networks 
influence the choices individuals make (178). Making healthier 
choices are critical for the future health of our bodies and our 
societies. The multifactorial character of lifestyle change in 
relation to obesity has been evaluated, taking all biological, 
economic, and societal aspects into account (15), indicating 
that no single change will have any major effect on obesity, and 
a systems approach or multi-domain approach is essential. This 
might be achieved on a society level but will need a concerted 
action of all stakeholders and would imply major shifts in eco-
nomic values, so is unlikely to happen with consensus of the 
current stakeholders. For example, in the current food supply 
chain, unhealthy food is cheap and healthy food is expensive, 
which does not help in making the right food choices for the 
majority of the population.
The food and nutrition market faces major challenges. The 
Western world suffers from too much and relatively cheap food 
with low-nutrient content but high-caloric density, mostly 
derived from low-cost ingredients like vegetable fat and sug-
ars. This is a trend rapidly adapted by the developing world 
(179). Food industry finds difficulties in providing scientific 
evidence that their products are healthy or have added health 
value (180), which might create added product value. Two key 
solutions here are the availability of foods with substantiated 
health benefits and the facilitation of personal healthy food 
choices, and acknowledging that food can be used as medicine, 
i.e., removing the artificial legal barrier to connect therapeutic 
or medical health claims to foods and nutrients (180, 181). 
These barriers historically make sense but impede the proper 
use to food in prevention of chronic disease or as therapy to treat 
lifestyle-related disease.
An essential part in this process is the individual’s self-empow-
erment in making healthy choices, by having access to reli able and 
actionable information to one’s personal health status through 
access to longitudinal personal health data, as described above. In 
shaping this new reality, self-empowerment needs to be embed-
ded in, and possibly even become the driver of a new healthcare 
economy based on personal data ownership (171). Development 
of systems diagnosis with preventive and personalized interven-
tions may create and trigger a series of commercial service-based 
health industry activities in the area of diagnostics, personal food 
solutions, food–pharma combinations, health advice systems, 
etc. Food companies may shift their product portfolio from 
product branding to product–service combinations (personal-
ized products connected to a diagnostic service), food services 
may be integrated into a health-based personal portfolio, ICT 
services will emerge based on a personal Biopassport (interpreta-
tion of an individual’s health data and relate this to actionable 
and understandable nutrition and lifestyle advice). Numerous 
business opportunities can be envisioned in a health economy 
which focuses on cure instead of care. These include pharma, 
food, retail, fitness, artificial intelligence, pharmacy, eHealth, 
diagnostics, coaching services, and workplace health programs. 
All of this needs to be developed based on evidence-based sci-
ence a within adequate regulatory–ethical frameworks. In other 
words, there is some work to be done.
Motivational coaching, both personal and by using ICT 
means, can be fully developed and implemented if financed in 
a healthcare system that appreciates the value of prevention and 
lifestyle therapy for lifestyle-related diseases. The developments 
in this area are rapid and promising (182, 183).
CONCLUSiON AND CALL TO ACTiON
In this article, we provide evidence for the reversibility of insulin 
resistance and the remission of type 2 diabetes, specifically by diet 
and lifestyle. Complete cure may be achieved if beta-cell func-
tion is still appropriate and complications have not yet occurred. 
We demonstrate that T2D is a “systems disease” with multiple 
organs and processes involved and consequently deserves to be 
treated in a personalized manner, if necessary in a “personalized 
lifestyle-personalized medicine combination.” Compliance to 
lifestyle change has been a major obstacle for implementation 
in health care, but the advancements in behavioral change 
technologies, eHealth, health literacy, and personal health data 
valorization now may allow for a switch from a research setting 
to real-life socioeconomic implementation. Enough arguments 
and instruments are currently available to implement a lifestyle-
based therapy for type 2 diabetes and other food-related lifestyle 
diseases and to extend this to a prevention and optimal health 
focused health care. Also, we argue that in doing so, an enormous 
economic gain will be achieved, which is well able to finance a 
lifestyle-based prevention and optimal health focused health care 
and economy. Since stakeholders, losses, and profits in this new 
economy will substantially differ from the current situation, the 
current healthcare industry will only slowly transit toward this 
new situation. Creative ways of implementation thus need to be 
explored. Ultimately, health data cooperatives may become the 
basis and drivers for this change, but this will take some time 
to develop into an economic reality. In the meantime, creative 
new “ecosystems” need to be explored that combine all necessary 
instruments for specific type 2 diabetes populations to be really 
effective. The goal would not only be to demonstrate its therapeu-
tic efficacy but also and possibly more important to demonstrate 
that a new health economy that provides the services (coaching, 
ITC, foods, diagnostics, medication, all of these personalized and 
integrated) can become profitable while significantly reducing the 
net healthcare costs.
Such ecosystems should preferably be regional, facilitat-
ing the simultaneous change of all relevant components if the 
“change system” to interact. This will allow community building, 
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